Cabaletta Bio (CABA) Return on Capital Employed (2019 - 2025)
Cabaletta Bio (CABA) recorded quarterly Return on Capital Employed of 135.34% in Q4 2025, down 33.66% quarter-over-quarter from 101.25% in Q3 2025, and down 6069.0% on a YoY basis from 2.27% in Q4 2024.
Cabaletta Bio (CABA) Return on Capital Employed (2019 - 2025) Analysis & Trends
Cabaletta Bio's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 135.34% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 6069.0% year-over-year to 135.34%; the TTM figure through Dec 2025 stood at 135.34% (down 6069.0% YoY), while the FY2025 annual figure was 137.89%, down 7280.0% from the prior year.
- Return on Capital Employed was 135.34% for Q4 2025 at Cabaletta Bio, down from 101.25% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 33.31% in Q1 2021 to a low of 135.34% in Q4 2025.
- Historically, Return on Capital Employed has averaged 59.44% across 5 years, with a median of 49.14% in 2024.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 2015 bps in 2024, then sank 6069 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 39.89% in 2021, then slumped by 43 bps to 57.09% in 2022, then surged by 34 bps to 37.81% in 2023, then plunged by 97 bps to 74.65% in 2024, then tumbled by 81 bps to 135.34% in 2025.
- The last three Return on Capital Employed figures came in at 135.34% (Q4 2025), 101.25% (Q3 2025), and 97.78% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Cabaletta Bio | 151.84 Mn | 18.24 Mn | - | -135.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -135.34% |
| Sep 30, 2025 | -101.25% |
| Jun 30, 2025 | -97.78% |
| Mar 31, 2025 | -95.14% |
| Dec 31, 2024 | -74.65% |
| Sep 30, 2024 | -60.89% |
| Jun 30, 2024 | -47.44% |
| Mar 31, 2024 | -37.43% |
| Dec 31, 2023 | -37.81% |
| Sep 30, 2023 | -40.28% |
| Jun 30, 2023 | -44.94% |
| Mar 31, 2023 | -57.58% |
| Dec 31, 2022 | -57.09% |
| Sep 30, 2022 | -56.82% |
| Jun 30, 2022 | -50.83% |
| Mar 31, 2022 | -43.87% |
| Dec 31, 2021 | -39.89% |
| Sep 30, 2021 | -38.39% |
| Jun 30, 2021 | -38.03% |
| Mar 31, 2021 | -33.31% |